Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07)

This study is a prospective, single arm, multi-center phase II clinical trial. The primary study objective is to evaluate the pathologic complete response（PCR） of treatment of TNBC breast cancer with neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab , including the incidences and types of adverse events. The secondary study objective is to observe and evaluate the event-free survival (EFS), Objective Response Rate(ORR), and radiologic complete response (rCR).

Trial Details

NCT ID
NCT07351487
Phase
PHASE2
Sponsor
First Affiliated Hospital of Zhejiang University
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab
Locations (sample)
  • Hefei, China|31.86389,117.28083
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Female patients aged 18-70 years old;
  • ECOG score is 0-1 points;
  • Histologically confirmed stage II-III (T1N1-3; T2-4N0-2) invasive breast cancer;
  • ER-negative, PR-negative, and HER2 receptor-negative. Alternatively, if ER and PR expression is less than 10% and HER2 receptor is negative, it is …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →